Sanofi-Glaxo Coronavirus Vaccine Passed The Trials

Sanofi-Glaxo coronavirus vaccine passed the trials. The vaccine was successful in early-stage clinical trials.

The new type of coronavirus (Covid-19) vaccine developed by French Sanofi and British GlaxoSmithKline managed to pass early stage clinical trials. In the statement made by the company today, it was said that people caught and recovered from coronavirus produced similar antibodies. The company has now announced that it will move to the final stage in testing, with more than 35,000 participants from different countries. Studies will be conducted on many variants, including the South African variant, in the studies scheduled to begin next week. Sanofi vaccine is estimated to be approved by regulators in the last quarter of 2021. This vaccine will play an important role in the course of the pandemic due to the many different variants emerging around the world and especially the poor countries' inability to supply vaccines. Thompson Triomphe of Sanofi Vaccine Division said, "As new variants emerge, more and more vaccines will be needed."